Ilyang Pharmaceutical Co.,Ltd (007570.KS)
KRW 12090.0
(-1.23%)
KRW 12090.0
(-1.23%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 85.15 Billion KRW | -0.65% |
| 2022 | 85.71 Billion KRW | -16.03% |
| 2021 | 102.08 Billion KRW | -0.93% |
| 2020 | 103.04 Billion KRW | -19.85% |
| 2019 | 128.56 Billion KRW | -10.69% |
| 2018 | 143.95 Billion KRW | -6.74% |
| 2017 | 154.36 Billion KRW | -0.44% |
| 2016 | 155.04 Billion KRW | -5.54% |
| 2015 | 164.14 Billion KRW | -14.05% |
| 2014 | 190.97 Billion KRW | 11.38% |
| 2013 | 171.47 Billion KRW | 14.74% |
| 2012 | 149.43 Billion KRW | 8.31% |
| 2011 | 137.97 Billion KRW | 2.91% |
| 2010 | 134.07 Billion KRW | 10.0% |
| 2009 | 121.88 Billion KRW | 25.89% |
| 2008 | 96.82 Billion KRW | 47.34% |
| 2007 | 65.71 Billion KRW | 36.62% |
| 2006 | 48.1 Billion KRW | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q2 | 98.02 Billion KRW | 6.9% |
| 2024 Q1 | 91.69 Billion KRW | 7.68% |
| 2023 FY | 85.15 Billion KRW | -0.65% |
| 2023 Q4 | 85.15 Billion KRW | -8.11% |
| 2023 Q3 | 92.67 Billion KRW | -3.81% |
| 2023 Q2 | 96.35 Billion KRW | 5.92% |
| 2023 Q1 | 90.96 Billion KRW | 6.12% |
| 2022 Q4 | 85.71 Billion KRW | -1.76% |
| 2022 Q3 | 87.25 Billion KRW | 3.42% |
| 2022 FY | 85.71 Billion KRW | -16.03% |
| 2022 Q1 | 82.47 Billion KRW | -19.21% |
| 2022 Q2 | 84.36 Billion KRW | 2.3% |
| 2021 Q4 | 102.08 Billion KRW | -0.48% |
| 2021 Q1 | 112.23 Billion KRW | 8.92% |
| 2021 Q2 | 102.52 Billion KRW | -8.66% |
| 2021 Q3 | 102.56 Billion KRW | 0.05% |
| 2021 FY | 102.08 Billion KRW | -0.93% |
| 2020 Q4 | 103.04 Billion KRW | -20.26% |
| 2020 Q1 | 130.46 Billion KRW | 1.48% |
| 2020 Q3 | 129.22 Billion KRW | -3.11% |
| 2020 FY | 103.04 Billion KRW | -19.85% |
| 2020 Q2 | 133.37 Billion KRW | 2.22% |
| 2019 Q2 | 138.11 Billion KRW | -1.15% |
| 2019 FY | 128.56 Billion KRW | -10.69% |
| 2019 Q4 | 128.56 Billion KRW | -8.98% |
| 2019 Q3 | 141.25 Billion KRW | 2.27% |
| 2019 Q1 | 139.72 Billion KRW | -2.94% |
| 2018 Q3 | 152.55 Billion KRW | 4.32% |
| 2018 Q4 | 143.95 Billion KRW | -5.64% |
| 2018 FY | 143.95 Billion KRW | -6.74% |
| 2018 Q1 | 156.63 Billion KRW | 1.47% |
| 2018 Q2 | 146.23 Billion KRW | -6.64% |
| 2017 FY | 154.36 Billion KRW | -0.44% |
| 2017 Q3 | 160.08 Billion KRW | 1.14% |
| 2017 Q2 | 158.28 Billion KRW | 0.17% |
| 2017 Q1 | 158.02 Billion KRW | 1.92% |
| 2017 Q4 | 154.36 Billion KRW | -3.57% |
| 2016 Q1 | 132.08 Billion KRW | 0.0% |
| 2016 Q3 | 166.38 Billion KRW | 1.11% |
| 2016 Q2 | 164.55 Billion KRW | 24.58% |
| 2016 FY | 155.04 Billion KRW | -5.54% |
| 2016 Q4 | 155.04 Billion KRW | -6.82% |
| 2015 FY | 164.14 Billion KRW | -14.05% |
| 2015 Q3 | 121.88 Billion KRW | -26.56% |
| 2015 Q2 | 165.96 Billion KRW | -13.1% |
| 2015 Q1 | 190.97 Billion KRW | 60.41% |
| 2014 FY | 190.97 Billion KRW | 11.38% |
| 2014 Q2 | 167.47 Billion KRW | -2.33% |
| 2014 Q4 | 119.05 Billion KRW | -39.29% |
| 2014 Q3 | 196.1 Billion KRW | 17.1% |
| 2014 Q1 | 171.47 Billion KRW | 0.0% |
| 2013 FY | 171.47 Billion KRW | 14.74% |
| 2013 Q1 | 149.43 Billion KRW | -1.36% |
| 2012 Q4 | 151.5 Billion KRW | 76.45% |
| 2012 Q3 | 85.86 Billion KRW | 4.03% |
| 2012 Q1 | 137.97 Billion KRW | -0.39% |
| 2012 FY | 149.43 Billion KRW | 8.31% |
| 2012 Q2 | 82.53 Billion KRW | -40.18% |
| 2011 Q2 | 79.39 Billion KRW | -40.78% |
| 2011 FY | 137.97 Billion KRW | 2.91% |
| 2011 Q1 | 134.07 Billion KRW | 0.19% |
| 2011 Q3 | 137.59 Billion KRW | 73.29% |
| 2011 Q4 | 138.51 Billion KRW | 0.67% |
| 2010 Q3 | 122.56 Billion KRW | 0.21% |
| 2010 Q4 | 133.81 Billion KRW | 9.18% |
| 2010 Q2 | 122.31 Billion KRW | 0.0% |
| 2010 FY | 134.07 Billion KRW | 10.0% |
| 2009 Q1 | 96.82 Billion KRW | -1.76% |
| 2009 FY | 121.88 Billion KRW | 25.89% |
| 2009 Q4 | 122.27 Billion KRW | 26.71% |
| 2009 Q3 | 96.5 Billion KRW | 0.0% |
| 2009 Q2 | 96.5 Billion KRW | -0.33% |
| 2008 Q2 | 83.12 Billion KRW | 26.49% |
| 2008 Q1 | 65.71 Billion KRW | 29.33% |
| 2008 Q4 | 98.55 Billion KRW | -18.35% |
| 2008 Q3 | 120.7 Billion KRW | 45.21% |
| 2008 FY | 96.82 Billion KRW | 47.34% |
| 2007 Q3 | 50.9 Billion KRW | -25.14% |
| 2007 FY | 65.71 Billion KRW | 36.62% |
| 2007 Q4 | 50.81 Billion KRW | -0.19% |
| 2007 Q2 | 68 Billion KRW | 0.0% |
| 2006 FY | 48.1 Billion KRW | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 48.25 Billion KRW | -76.477% |
| Yuhan Corporation | 230.07 Billion KRW | 62.985% |
| Yuhan Corporation | 230.07 Billion KRW | 62.985% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -116.102% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -116.102% |
| Yuyu Pharma, Inc. | 39.4 Billion KRW | -116.102% |
| Ildong Holdings Co., Ltd. | 382.06 Billion KRW | 77.71% |
| Samil Pharmaceutical Co.,Ltd | 175.87 Billion KRW | 51.58% |
| Dong-A Socio Holdings Co., Ltd. | 691.88 Billion KRW | 87.692% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 49.988% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 49.988% |
| JW Pharmaceutical Corporation | 170.28 Billion KRW | 49.988% |
| SAMSUNG PHARM. Co., LTD. | 595.48 Million KRW | -14200.902% |
| Chong Kun Dang Holdings Corp. | 468.03 Billion KRW | 81.805% |
| Dong Sung Bio Pharm.Co.,Ltd. | 43.27 Billion KRW | -96.798% |
| HANDOK Inc. | 300.01 Billion KRW | 71.614% |
| Jeil Pharma Holdings Inc | 173.03 Billion KRW | 50.783% |
| Kukje Pharma Co., Ltd. | 30.66 Billion KRW | -177.737% |
| Bukwang Pharmaceutical Co., Ltd. | 79.38 Billion KRW | -7.272% |
| Aprogen pharmaceuticals,Inc. | 180.99 Billion KRW | 52.95% |
| Ilsung Pharmaceuticals Co., Ltd. | 238.12 Million KRW | -35662.509% |
| Daewon Pharmaceutical Co., Ltd. | 146.04 Billion KRW | 41.691% |
| Yungjin Pharm. Co., Ltd. | 66.88 Billion KRW | -27.328% |
| Boryung Corporation | 204.21 Billion KRW | 58.299% |
| Hyundai Pharmaceutical Co., Ltd. | 39.2 Billion KRW | -117.217% |
| Samjin Pharmaceuticals Co., Ltd. | 118.63 Billion KRW | 28.219% |
| Ilyang Pharmaceutical Co.,Ltd | 85.15 Billion KRW | 0.0% |
| Suheung Co., Ltd. | 467.85 Billion KRW | 81.798% |
| Kwang Dong Pharmaceutical Co., Ltd. | 235.64 Billion KRW | 63.86% |
| Hanall Biopharma Co.,Ltd | 1.29 Billion KRW | -6498.828% |
| Whan In Pharm Co.,Ltd. | 632.02 Million KRW | -13374.113% |
| MYUNGMOON Pharm co.,Ltd | 90.48 Billion KRW | 5.882% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -84.523% |
| Shin Poong Pharm.Co.,Ltd. | 46.15 Billion KRW | -84.523% |
| Korea United Pharm Inc. | 40.33 Billion KRW | -111.11% |
| CKD Bio Corp. | 146.92 Billion KRW | 42.039% |
| Daewoong pharmaceutical Co.,Ltd | 469.68 Billion KRW | 81.869% |
| JW Holdings Corporation | 554.58 Billion KRW | 84.644% |
| REYON Pharmaceutical Co., Ltd. | 225.05 Billion KRW | 62.16% |
| Hanmi Pharm. Co., Ltd. | 572.86 Billion KRW | 85.134% |
| Dong-A ST Co., Ltd. | 406.7 Billion KRW | 79.061% |
| Chong Kun Dang Pharmaceutical Corp. | 219.76 Billion KRW | 61.249% |
| JW Lifescience Corporation | 46.31 Billion KRW | -83.88% |
| Ildong Pharmaceutical Co., Ltd. | 217.84 Billion KRW | 60.907% |
| Jeil Pharmaceutical Co.,Ltd | 84.96 Billion KRW | -0.229% |
| Hana Pharm Co., Ltd. | 26.53 Billion KRW | -220.957% |